Clinical Trials Browser

Breast Neoplasms

Breast Neoplasms

Anatomic Stage I Breast Cancer AJCC v8

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

Breast Neoplasms

Triple Negative Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

Anatomic Stage IV Breast Cancer AJCC v8

Breast Neoplasms

Triple Negative Breast Neoplasms

Breast Neoplasms

Advanced Breast Carcinoma

Breast Cancer Metastatic

Breast Neoplasms, Inflammatory Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Triple Negative Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Triple Negative Breast Neoplasms

Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

Edema, Erythema, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Inflammatory Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

Breast Neoplasms

Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

Clinical Trials

EMPRESS

Preoperative Single-Fraction Radiotherapy in Early Stage Breast Cancer

Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer

CARABELA

Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.

TRANSCENDER

Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer

FELINE

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer

Fulvestrant With or Without Ganetespib in HR+ Breast Cancer

KEYLYNK-009

Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)

Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer

AMTEC IIT: Phase 2 Multiarm Study in TNBC

Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

AMEERA-3

Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer

Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer

T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)

Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer

Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer

Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer

Next MONARCH 1

Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer

NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer

Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa

OPALESCENCE

Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy

INTEGRAL

Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy

Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer

Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy

Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer

Study Assessing the Potential for Reduced Rates of Implant Failure Using Multi-Beam Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer Patients With Implant Reconstructions

Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

BYLieve

neoMono

MK-7119-001

ELPIS

LDTam

NOVEMBER

Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease

A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer